ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology, focusing on Gene & Genome Synthesis and Assembly
ITI Life Sciences issued a Call for Expressions of Interest from organisations or individuals with expertise in synthetic biology techniques that could be applied to Gene & Genome Synthesis and Assembly. ITI Life Sciences' is seeking to commission a new R&D programme to develop novel technologies that can be further developed to create high-value commercial products. Typically, R&D programmes will receive in the range of £2-5 million (US$4-10 million) over an anticipated term of 18-36 months, and are expected to lead to the creation of centres of research excellence in Scotland.
Synthetic Biology is a highly promising new area of biotechnology that merges biology with engineering to create new microorganisms programmed to perform complex biological processes for specific industrial applications. It is a significant advance on current genetic engineering technologies owing to the level of both engineering involved and the controllability of the process.
ITI Life Sciences' market and technology analysis process (foresighting) has concluded that such applications are expected to address market needs in a variety of sectors of high commercial and societal value, ranging from bioenergy, chemical synthesis, drug and vaccine development, biosensor development and tissue engineering. As such, Synthetic Biology is attracting considerable interest from academia, industry and the financial community, and major opportunities exist in the development of enabling technologies to drive this new area forward.
Extensive analysis conducted by ITI Life Sciences, involving engagement and consultation with industry and academia, focusing on trends in Synthetic Biology, has identified key enabling technologies necessary for this field to reach a critical mass (a detailed market foresighting report is available to members of ITI Scotland). As a result of this analysis, ITI Life Sciences is keen to identify R&D 'packages' to form the basis of a commercially viable research programme, the goal of which is to develop innovative tools, strategies and methods that enable Gene & Genome Synthesis and Assembly, and that can be further developed to create commercial products.
Responses are invited from companies, agencies, institutes, academia and individuals. No geographical restrictions apply and ITI Life Sciences welcomes responses to this call from non-UK organisations. ITI Life Sciences is committed to helping its partners achieve success and ensuring the successful onward commercialisation of programme outputs.
Further details of the Call for Expressions of Interest are available online. Responses must be received no later than the 5 May 2008.
Most read news
Topics
Related link
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
GE Healthcare and BAC start collaboration in biopharmaceutical purification
CuraGen and TopoTarget Initiate Phase Ib Clinical Trial with PXD101 for Advanced Colorectal Cancer - Proof-of-Concept Trial Evaluating PXD101 Combination Therapy with 5- fluorouracil for Advanced Solid Tumors and Colorectal Cancer
Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research - Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million
Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA
